

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia ID3924

#### Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> Kyowa Kirin (burosumab)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Metabolic Support UK</li> <li>• Findacure</li> <li>• Genetic Alliance</li> <li>• Gene People</li> <li>• Pain Concern</li> <li>• Pain UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• XLH UK</li> <li>•</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Dental Association</li> <li>• British Geriatrics Society</li> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Orthopaedic Association</li> <li>• British Society for Paediatric Endocrinology and Diabetes</li> <li>• British Society for Rehabilitation Medicine</li> <li>• British Society for Rheumatology</li> <li>• Physiotherapy Pain Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Endocrinology</li> <li>• UK Clinical Pharmacy Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• National Services Division</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Abbvie (paricalcitol)</li> <li>• Alturix (phosphate)</li> <li>• Atnahs Pharma UK (calcitriol)</li> <li>• Cubic Pharmaceuticals (ergocalciferol)</li> <li>• Essential Healthcare (alfacalcidol)</li> <li>• Ethypharm Group (phosphate)</li> <li>• Fresenius Kabi (phosphate)</li> <li>• HealthAid (ergocalciferol)</li> <li>• Neon Healthcare (alfacalcidol)</li> <li>• Rhodes Pharma (ergocalciferol)</li> </ul>

Provisional stakeholder list for the single technology appraisal of burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia ID3924 Issue date: March 2022

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Addenbrooke's, Cambridge University Hospitals NHS Foundation Trust,</li> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Erewash CCG</li> <li>• NHS Haringey CCG</li> <li>• Queen Elizabeth Hospital Birmingham, University Hospital Birmingham Foundation Trust, Department of Endocrinology</li> <li>• Royal National Orthopaedic Hospital, NHS Trust</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• RPH Pharmaceutical (ergocalciferol)</li> <li>• Strides Pharma (alfacalcidol)</li> <li>• Teva UK (calcitriol)</li> <li>• Theramex HQ UK (alfacalcidol)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bone Research Society</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane UK</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Orthopaedic Research UK</li> <li>• Pain Relief Foundation</li> <li>• Society of Back Pain Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• UK Health Security Agency</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the final draft guidance.

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the final draft guidance.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final draft guidance for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.